Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28965160 | 0.90 | PAOX (0.31) | — | |
| SCHEMBL142707 | 0.84 | MGAM (0.31) | ALDH1A1GLA | |
| SCHEMBL462606 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNASLC15A2GLA | |
| SCHEMBL10071372 | 0.75 | SMN1; SMN2 (0.38) | ALDH1A1 | |
| SCHEMBL829438 | 0.75 | SMN1; SMN2 (0.35) | ALDH1A1GLA | |
| SCHEMBL28381750 | 0.75 | PSMB8 (0.33) | GLA | |
| SCHEMBL4618888 | 0.74 | GLA (0.32) | GLA | |
| SCHEMBL10071373 | 0.74 | SMN1; SMN2 (0.40) | ALDH1A1 | |
| SCHEMBL12896267 | 0.74 | SMN1; SMN2 (0.40) | ALDH1A1 | |
| SCHEMBL469600 | 0.74 | SMN1; SMN2 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4388014-A1 | MULTIVALENT ANTI-VARIANT FC-REGION ANTIBODIES AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2024-06-26 | — | — | EP | claimed |
| CN-117858905-A | Multivalent anti-variant FC region antibodies and methods of use | 豪夫迈·罗氏有限公司 | 2024-04-09 | — | — | CN | claimed |
| WO-2023021055-A1 | MULTIVALENT ANTI-VARIANT FC-REGION ANTIBODIES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-02-23 | — | — | WO | claimed |
| WO-2010078376-A2 | FC-SPECIFIC POLYMER-CONJUGATED ANTIBODIES AND THEIR DIAGNOSTIC USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| EP-0382781-B1 | COMPOSITION FOR TREATING CANCERS CHARACTERIZED BY OVER-EXPRESSION OF THE C-FMS PROTO-ONCOGENE | GENETICS INSTITUTE, INC. (US) | 1993-09-29 | — | — | EP | claimed |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TALLAC THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Tallac Therapeutics, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4257186-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4388014-A1 | MULTIVALENT ANTI-VARIANT FC-REGION ANTIBODIES AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| CN-117858905-A | Multivalent anti-variant FC region antibodies and methods of use | 豪夫迈·罗氏有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| US-5998157-A | CONTACTING SAMPLE WITH ANTIBODY AND BINDING PARTNER IN PRESENCE OF ACYLATED PROTEIN AGGREGATE | ROCHE DIAGNOSTICS GMBH (DE) | 1999-12-07 | — | — | US | disclosed |
| WO-1998056353-A1 | INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS | MALIK NAVID (GB) | 1998-12-17 | — | — | WO | disclosed |
| US-5658725-A | REDUCING NON-SPECIFIC INTERACTIONS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-08-19 | — | — | US | disclosed |
| EP-0685070-A1 | ACYLATED PROTEIN AGGREGATES AND THEIR USE IN SUPPRESSING INTERFERENCE IN IMMUNOASSAYS | Roche Diagnostics GmbH (DE) | 1995-12-06 | — | — | EP | disclosed |
| EP-0684956-A1 | ACYLATED PROTEIN AGGREGATES AND THEIR USE IN ENHANCING SIGNALS IN AN IMMUNOASSAY TESTING FOR ANTIBODIES | Roche Diagnostics GmbH (DE) | 1995-12-06 | — | — | EP | disclosed |
| WO-1995017668-A1 | ACYLATED PROTEIN AGGREGATES AND THEIR USE IN SUPPRESSING INTERFERENCE IN IMMUNOASSAYS | BOEHRINGER MANNHEIM GMBH (DE) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995017427-A1 | ACYLATED PROTEIN AGGREGATES AND THEIR USE IN ENHANCING SIGNALS IN AN IMMUNOASSAY TESTING FOR ANTIBODIES | BOEHRINGER MANNHEIM GMBH (DE) | 1995-06-29 | — | — | WO | disclosed |
| EP-0382781-B1 | COMPOSITION FOR TREATING CANCERS CHARACTERIZED BY OVER-EXPRESSION OF THE C-FMS PROTO-ONCOGENE | GENETICS INSTITUTE, INC. (US) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | ALDH1A1 3966/4885LMNA 3666/4885SLC15A2 2765/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ALDH1A1 3966/4885LMNA 3666/4885SLC15A2 2765/4885 |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | ALDH1A1 2398/4885LMNA 3368/4885SLC15A2 3717/4885 |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | UNG, DUT, TYMP | ALDH1A1 3842/4885LMNA 926/4885SLC15A2 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.